Phase 4 N=62 Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department
Pain
Primary: Side Effects — 21; 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=7 Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
Cerebral Hemorrhage · Cerebral Edema · Intracerebral Hemorrhage
Primary: Patient Tolerance of Conivaptan — 0; 0; 1; 0 Participants
Phase 4 N=1,106 Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period — NA; NA; NA; NA weeks — p=0.006
Phase 1 N=34 Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
Prostatic Hyperplasia
Primary: Maximum Measured Concentration (Cmax) — 8826; 8856 pg/mL
Phase 1 N=25 A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
Advanced Cancer · Metastatic Cancer
Primary: Maximum Tolerated Dose (MTD) of LY3076226 — 5.0 milligrams
Phase 2 N=163 Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Chronic Ischemic Stroke
Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743
N/A N=33 Impact of Switching to Non-Menthol Cigarettes Among Smokers
Tobacco Use
Primary: Total Number of Cigarettes Smoked — 2.2 cigarettes per day
N/A N=20 A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
Nasolabial Fold · Safety
Primary: Response Rate in Treatment of Nasolabial Fold (NLF) Based on a Scale — 63.2; 68.4 percentage of participants
N/A N=30 Self-Management for Youth and Families Living With SCD - SMYLS
Sickle Cell Disease
Primary: Rates of Recruitment — 14 weeks
Phase 2 N=44 Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Acute Myeloid Leukemia
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
N/A N=102 Cold Plasma for Dental Restoration and Caries Prevention
Dental Restoration · Caries
Primary: Number of Decayed, Missing and Filling Teeth (DMFT) — 6.29; 5.14 teeth
N/A N=29 3D MR Versus 3D CT for Glenohumeral Arthritis
Arthritis · Glenohumeral Osteoarthritis
Primary: Glenoid Version — 12.1; 11.4 degrees
Phase 3 N=66 Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression
Depression
Primary: Change in Dopamine Transporter Binding
N/A N=41 Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite
Morbid Obesity · Noninvasive Ventilation · Deep Sedation
Primary: Ability to Maintain Oxygenation — 0.55; 0.61 manipulations
N/A N=319 Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial
Drug-induced Nausea and Vomiting
Primary: Number of Participants Experiencing Symptoms — 45; 19 Participants — p=0.00